GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » 3-Year EPS without NRI Growth Rate

Vectus Biosystems (ASX:VBS) 3-Year EPS without NRI Growth Rate : 33.80% (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems 3-Year EPS without NRI Growth Rate?

Vectus Biosystems's EPS without NRI for the six months ended in Dec. 2024 was A$-0.02.

During the past 3 years, the average EPS without NRI Growth Rate was 33.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 11.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 9 years, the highest 3-Year average EPS without NRI Growth Rate of Vectus Biosystems was 33.80% per year. The lowest was -20.80% per year. And the median was 12.50% per year.


Competitive Comparison of Vectus Biosystems's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Vectus Biosystems's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vectus Biosystems's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vectus Biosystems's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Vectus Biosystems's 3-Year EPS without NRI Growth Rate falls into.


;
;

Vectus Biosystems 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Vectus Biosystems  (ASX:VBS) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Vectus Biosystems 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectus Biosystems Business Description

Industry
Traded in Other Exchanges
N/A
Address
26-34 Dunning Avenue, Unit 5, Ground Floor, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. It operates in one segment, being pharmaceutical research and development.

Vectus Biosystems Headlines

No Headlines